Filling the Need for New Antiarrhythmic Drugs to Prevent Shocks from Implantable Cardioverter Defibrillators

Journal of the American College of Cardiology

Volumn 43, Issue 1, 2004, Pages 44-46

  Curtis, Anne B ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; SOTALOL;

ANTITACHYCARDIA PACING; CARDIOTOXICITY; CATHETER ABLATION; CLINICAL TRIAL; DEFIBRILLATOR; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTRIC SHOCK; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; INOTROPISM; LUNG FIBROSIS; MORTALITY; NOTE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 0346422342     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.014     Document Type: Editorial

References (16)

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
2. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
3. Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
4. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
5. Schaumann A, von zur Muhlen F, Herse B, Gonska BD, Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998;97:66-74.
6. Wathen MS, Sweeney MO, DeGroot PJ, et al., for the PainFREE Investigators. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001;104:796-801.
7. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997;96:1525-31.
8. Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol 1998;82:744-8.
9. Steinberg JS, Martins J, Sadanandan S, et al., for the AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001;142:520-9.
10. Singh SN, Fletch RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77-82.
11. Dolack GL. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE Trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Am J Cardiol 1994;73:237-41.
12. O'Toole M, O'Neill G, Kluger J, Bonney SL, Friedrich T. Efficacy and safety of oral dofetilide in patients with an implanted defibrillator: a multicenter study (abstr). Circulation 1999;100:1794.
13. Torp-Pedersen C, Moller M, Block-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
14. Pacifico A, Hohnloser SH, Williams JH, et al., for the d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999;340:1855-62.
15. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001;88:974-9.
16. Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004;43:39-43.